AI Weekly Malaysia

Epic, which makes the MyChart patient portal used to maintain over 320 million patient records in the US, has paused most of its product development for roughly six weeks to fix security bugs, per founder and CEO Judy Faulkner speaking to Modern Healthcare. The flaws surfaced after a deployment of Anthropic's frontier cybersecurity model, Mythos, and chief security officer Stirling Martin told The Times that some customer configurations of MyChart could let outsiders read patient records without leaving any entry in the software's logs. Martin said the model did not establish whether records could also be altered undetected, but Epic judged the risk serious enough to remediate; TechCrunch notes Epic has not disclosed the nature of the bugs.

Why: The concrete lesson is the logging gap, not the vendor: a read of patient records that leaves no trace in application logs defeats detection and audit entirely, and that class of bug is exactly what an AI security model found here at scale. If you ship anything with a permission model — patient data, tenant data, customer records — test whether privileged or misconfigured access paths produce an audit entry, and treat 'no log line' as a bug of its own. Also note the release-planning implication: a six-week freeze on most product development is what a serious finding costs, so teams running continuous release trains should decide in advance what triggers a stop-ship versus a patch-forward.

EliseAI, founded in 2017, raised $350M at a $4B valuation — double its Series E valuation from last August — in a round co-led by Andreessen Horowitz and Bessemer Ventures. The company automates administrative work for US housing and healthcare operators, says its software runs in 1 in 6 US apartments, and reported passing $200M ARR this summer. Earlier this month it launched an in-platform AI "teammate" called Apollo that acts across leasing, maintenance and renewals roles, per co-founder and CEO Minna Song.

Why: The concrete signal here is not the round size but the $200M ARR attached to a narrow vertical back-office agent, plus a distribution detail — 1 in 6 US apartments. If you are building an AI agent product, this is evidence that owning a specific operational workflow (leasing, insurance verification, scheduling) and selling into companies that already have that pain beats a generic horizontal assistant. There is no Malaysia or SEA element in this item, so it should not be framed as local news.

Blue Cross Blue Shield Association estimated that hospitals' use of AI-assisted medical coding contributed to $942 million in additional costs for its health plans between 2023 and 2025. BCBSA said much of the increase came from secondary diagnoses that moved patients into higher-paying reimbursement. AI is now used in medical billing and coding to translate procedures and diagnoses into standardized codes that appear on insurance claims and patient bills, while experts warn of an administrative AI arms race in U.S. healthcare.

Why: For most Malaysian developers and founders this is not a local policy change and requires no immediate action. If you build AI for claims, billing, or insurance workflows, it is a concrete case where AI-assisted coding shifted reimbursement by $942 million and drew public blame from a payer, so audit trails and explainability are not optional before deployment.

TechCrunch's Equity podcast episode features Farooq Abbasi, founder and general partner of Preface Ventures and an investor in Neko Health, discussing the company's $700 million raise to build a preventative body-scanning business. The episode covers what Neko's $500 scan actually includes, how the company keeps that price down, why Abbasi sees low primary-care utilization as one of the biggest problems in U.S. healthcare, and his view that some consumer-health startups may be overfunded. The show also notes Midjourney is building its own body scanner and that Function Health has raised significant capital for a preventative-health platform.

Why: This is a podcast promo, not new product or pricing news, so nothing here changes what you build this week. The one reusable number is the $500 scan price and the claim that Neko keeps it down through its own operations — if you are modelling consumer health or diagnostics pricing for a Malaysian or SEA market, that unit-economics question (what a scan must cost to be repeatable without insurance) is the part worth stealing, and the episode reportedly discusses it. Otherwise treat the $700M figure as a funding headline, not a signal about your roadmap.

Konrad Zieliński, who lost his voice to cancer while a student at the University of Warsaw, founded Uhura Bionics in 2023 to build non-surgical wearable voice devices for laryngectomees — people whose larynxes have been removed — as an alternative to handheld robotic-sounding speak-and-spell devices or surgically implanted prostheses requiring ongoing maintenance. The company sells two models: a basic one at $500 and a high-end 'Whitney' (named after Whitney Houston) at $1,500, currently as wellness devices so buyers pay out of pocket, while pursuing Class I medical device classification in Europe and later the U.S. to unlock partial insurance reimbursement. It was picked for TechCrunch Disrupt 2026's Battlefield 200, and its roadmap includes higher-pitched voice options for women plus personalization so users don't all sound alike.

Why: The transferable lesson is the regulatory sequencing, not the gadget: Uhura sells at $500–$1,500 direct to users as a 'wellness device' to ship now, then pursues the lowest-risk Class I medical classification specifically to unlock partial insurance reimbursement. Any founder building health-adjacent hardware should note that the reimbursement path — not the engineering — is what changes who can afford the product. There is no Malaysian or Southeast Asian angle in this item; it is a founder profile, so treat it as a case study rather than news you must act on.

Neko Health, the Swedish body-scan startup co-founded by Spotify's David Ek and Hjalmar Nilsonne, has opened in New York after raising nearly $1 billion and building a global waitlist it says tops 300,000 people. The one-hour scan screens blood, skin, and metabolism using computer vision, and is sold direct to consumers at $500 — not covered by insurance, but positioned as HSA-eligible. Investor Farooq Abbasi of Preface Ventures says his blood panel went from 15 biomarkers in an earlier generation to 55 now, and that the company is eyeing wider U.S. expansion while still facing scaling and regulatory approval work.

Why: There is no direct action here for Malaysian developers or founders — this is a U.S. consumer health expansion, not tooling, infrastructure, or policy that touches your stack. The one transferable detail is the pricing model: a $500 cash-pay, insurance-bypassing screening product with a 300,000-person waitlist, which is a data point if you are building any direct-to-consumer health or diagnostics product in Malaysia's private healthcare market. Otherwise treat it as context, not a decision trigger.

Grindr announced on Sept 30, 2026 that it is acquiring PurposeMed, the parent company of HIV-prevention telehealth provider Freddie, for $250 million — $190 million in cash plus $60 million in Grindr common stock, with up to $70 million more in cash tied to Freddie's 2027 performance and payable in 2028. It is Grindr's first major acquisition since it was founded in 2009, is expected to close in Q4, and extends the Woodwork telehealth service Grindr launched in 2025. CEO George Arison told CNBC the new line could be as profitable as the core dating business and 'the same size, if not bigger.'

Why: There is no direct impact here for Malaysian developers, AI/ML builders, or agent users — this is consumer health M&A with no tooling, API, or infrastructure change attached. The one transferable detail for founders is the deal structure: 76% cash, 24% stock, plus a $70M earnout keyed to 2027 performance and paid in 2028, which is a concrete template for how a larger acquirer prices an unproven adjacent line rather than paying it all upfront. Treat the rest as an anecdote about a niche consumer app buying its way into a regulated service vertical instead of building it.

TechCrunch's Equity podcast episode (Sept 30, 2026) examines Neko Health, the body-scanning startup from Spotify founder Daniel Ek that raised $700 million, and asks whether the scan is worth it as it expands into the US market. Host Dominic-Madori Davis speaks with Farooq Abbasi of Preface Ventures, an investor in Neko, about how it compares with other consumer preventative-health companies and what would have to happen for body scanning to be absorbed into the broader healthcare system. The episode also notes Midjourney is building its own body scanner and that Function Health has raised significant capital for a preventative-health platform.

Why: There is nothing here for a working builder to act on: no pricing, no scan accuracy data, no availability outside the US, and no Malaysian or SEA angle. The only transferable signal is category-level — $700M went into consumer body scanning, Function Health raised significant capital for the same space, and Midjourney (an image-generation company) is building a scanner, which is a data point on how AI-adjacent companies are pushing into physical diagnostics. If you are weighing a healthtech idea, treat this as evidence that US consumer preventative health is heavily funded, not as evidence about local demand or regulatory feasibility.

A study by the International Agency for Research on Cancer (IARC), a WHO arm, published Monday in The Lancet Oncology estimates that infections caused 2.3 million new cancer cases in 2024 — 12 per cent, or roughly one in eight, of all new cases worldwide. H. pylori led with 760,000 cases (mostly eastern Asia), HPV followed at nearly 750,000 (with high rates in sub-Saharan Africa), and HBV/HCV were linked to a significant share of liver cancers; the researchers expanded their list of infection-linked cancers to include 16 additional ones, adding HIV's link to cervical cancer and Merkel cell polyomavirus. Co-author Gary Clifford, a cancer epidemiologist described in the article as based in Lyon, France, said new infectious agents have been identified and evidence has grown for the range of cancers known agents can cause.

Why: There is no actionable takeaway here for developers, founders, or AI tooling users — this is epidemiology, not software, and nothing in the article changes what anyone in this audience should build, buy, or configure. The only relevant signal is meta: the item reached 282 points and 147 comments on Hacker News, which says more about what the HN front page rewards than about anything this community ships with. If you cover it at all, cover it as an example of a non-tech story that outranks dev tooling, not as news you need to act on.

The headline says a fifth unvaccinated person has died of measles and that the CDC is not counting all deaths, but the retrieved page contains only a cookie-consent and privacy notice — no article body, no case counts, no dates beyond the 2026-09-30 publish timestamp, and no named locations. Nothing in the supplied text supports any technical or builder-facing detail. Treat this as an unverified headline with zero usable content.

Why: Nothing here changes what a developer, AI learner, or founder should build or decide — and the fetched content is a consent wall, not the article. The practical lesson is about tooling: a scraper or news-summarizing agent hitting this URL gets a 200 response with cookie-banner text, and a naive summarizer would invent measles details that are not in the source. If you run any ingestion pipeline over news URLs, verify you detect consent/boilerplate-only pages before summarizing.

Ars Technica published an item titled "Most powerful obesity drug yet: People lost up to 25% of weight in trial," but the retrieved page content contains only the site's cookie and privacy-consent boilerplate. No drug name, trial phase, participant count, duration, comparator, side-effect data, manufacturer, or pricing is present in the text. Nothing about AI, developer tooling, databases, agents, SaaS, or Malaysian/SEA tech appears.

Why: Nothing actionable for this audience: there is no drug name, no trial details, and no pricing or availability date to act on, so no one should change a build, a tool choice, or a roadmap because of this item. Treat it as a headline only, and wait for a version with actual trial data before discussing it.